IPP Bureau
Thyrocare launches diagnostic lab in Bhagalpur
By IPP Bureau - May 03, 2025
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
By IPP Bureau - May 03, 2025
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification
By IPP Bureau - May 03, 2025
This significant milestone enhances our global regulatory standing
Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
By IPP Bureau - May 03, 2025
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
USFDA inspection at Concord Biotech’s API facility at Dholka
By IPP Bureau - May 03, 2025
These observations are procedural in nature and none of them are related to data integrity
Vanta Bioscience receives GLP compliance re-certification
By IPP Bureau - May 03, 2025
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
Neuland Laboratories completes USFDA inspection at Unit 2
By IPP Bureau - May 03, 2025
The FDA issued Form 483 with one observation related to building and facility management
Sanofi Consumer Healthcare India Q1 PAT up 12.9%
By IPP Bureau - May 03, 2025
The Q1 2025 also witnessed a successful launch of Allegra D
Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP
By IPP Bureau - May 02, 2025
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr
By IPP Bureau - May 01, 2025
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Sigachi Industries signs MoU with Respilon Group
By IPP Bureau - May 01, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility
By IPP Bureau - May 01, 2025
The Subsidiary has received one inspectional observation in Form 483
Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules
By IPP Bureau - May 01, 2025
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
By IPP Bureau - May 01, 2025
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals
By IPP Bureau - May 01, 2025
Alembic Pharmaceuticals commissions new facility at Pithampur
